Tirzepatide reduces thirst signals, so you must drink intentionally even when not feeling thirsty

Key Clinical Findings from Rose Pharma Studies: Proven Appetite Suppression: Completed proof of concept study, demonstrated that ROSE-010 significantly reduces food consumption and slows gastric emptying Rapid Onset, Short Duration: Begins working within 20 minutes and clears within a few hours, minimizing side effects Reduced GI Side Effects: Unlike long-acting GLP-1s, ROSE-010s shorter half-life lowers the period of nausea and GI distress Improved Tolerability: Targets appetite without prolonged drug exposure, making it an ideal maintenance therapy Why the Market Needs ROSE-010 60-85% of GLP-1 patients need an effective weight loss maintenance strategy Current solutions focus on weight lossPeople need long-term weight loss management options ROSE-010 offers a flexible, meal-time approach to prevent weight regain Real-world data shows that long-term GLP-1 adherence is low yet patients need tools to sustain their progress

52 Since September 2024, subcutaneous tirzepatide has been TGA approved for the treatment of overweight and obesity
While you need cortisol in small amounts to naturally wake up in the morning and respond to immediate threats, chronic or unnatural spikes in cortisol are the absolute enemy of a lean, healthy physique
Complete our waitlist form to be notified when FOXO4-DRI becomes available
Every CoLaz clinic works to these standards, and we would rather turn away an unsuitable case than treat it